Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors

US10550099B2 · kind B2 · utility

Assignee

• FORMA Therapeutics, Inc. · US

Inventors

• Jian Lin · Watertown, US
• Anna Ericsson · Keyano, CA
• Ann-Marie Campbell · Monroe, US
• Gary Gustafson · Ridgefield, US
• Zhongguo Wang · Lexington, US
• R. Bruce Diebold · Waltham, US
• Susan Ashwell · Plainsboro, US
• David R. Lancia, Jr. · Boston, US
• Justin Andrew Caravella · Cambridge, US
• Wei Lu · Newton, US

Key dates

• Filing date: Mar 1, 2019
• Grant date: Feb 4, 2020
• Expiry date: Mar 1, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.